Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases. The company offers antibody discovery and development services; and a range of antibody engineering services for various stages of therapeutic and diagnostic antibody development. It also engages in the humanization of monoclonal antibodies. In addition, the company provides antibody sequencing services; custom expression and purification of recombinant proteins; transient protein expression; and stable cell line development services, as well as antibody analysis services. It serves pharmaceuticals, biotech, and diagnostic companies in the United Kingdom, the rest of Europe, North America, and the rest of the World. The company has a collaboration partnership with Celonic AG for the development of high yield stable cell lines. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom. The company trades on AIM exchange marketplace. The company headquarter is located in United Kingdom. The company was established in the 2017. The company's ISIN is GB00BDQZGK16.
TickerFAB
Long NameFusion Antibodies PLC
Short NameFusion Antibodies
SectorHealthcare
SubsectorBiotechnology
Subsector 2Health Care
CurrencyGBX
ISINGB00BDQZGK16